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Myotonic dystrophy is caused by two different mutations: a (CTG)n expansion in 3V UTR region of the DMPK gene (DM1) and a (CCTG)n
expansion in intron 1 of the ZNF9 gene (DM2). The most accredited mechanism for DM pathogenesis is an RNA gain-of-function. Other findings
suggest a contributory role of DMPK-insufficiency in DM1. To address the issue of ZNF9 role in DM2, we have analyzed the effects of (CCTG)n
expansion on ZNF9 expression in lymphoblastoid cell lines (n =4) from DM2 patients. We did not observe any significant alteration in ZNF9
mRNA and protein levels, as shown by QRT-PCR and Western blot analyses. Additional RT-PCR experiments demonstrated that ZNF9 pre-
mRNA splicing pattern, which includes two isoforms, is unmodified in DM2 cells. Our results indicate that the (CCTG)n expansion in the ZNF9
intron does not appear to have a direct consequence on the expression of the gene itself.
D 2005 Elsevier B.V. All rights reserved.Keywords: Myotonic dystrophy; DM2; CCTG expansion; ZNF9 expression; Splicing isoform1. Introduction
Myotonic dystrophy (DM) is an autosomal dominant
multisystem disorder and the most common form of muscular
dystrophy in adults [1]. It is characterized by myotonia with
muscle weakness and wasting, but involves also defects in the
heart, ocular and endocrine systems. One form of the disorder
(DM1, Steinert disease; OMIM 160900) is caused by an
unstable (CTG)n repeat in the 3V untranslated region of the
dystrophia myotonica protein kinase gene (DMPK; OMIM
605377) on chromosome 19q13.3 [2–4]. A second form of
myotonic dystrophy (DM2; OMIM 602668) is instead associ-
ated with a (CCTG)n expansion range between 75 to
approximately 11,000 repeats in the first intron of the ZNF9
gene on chromosome 3q21.3 [5–7]. Patients with DM2 show0925-4439/$ - see front matter D 2005 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2005.11.004
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conduction arrhythmias, iridescent cataracts, male hypogonad-
ism and insulin insensitivity. Despite of this striking similarities
with DM1, DM2 does not show a congenital form, a severe
central nervous system involvement and, in general, the degree
of muscle weakness and wasting is milder and predominantly
proximal at onset [8]. The spectrum and the severity of
extramuscular manifestations may also be variable suggesting
the existence of a multisystemic myotonic syndrome with a
common genetic background [9]. Since the identification of the
expansion in DMPK 3V untranslated region, the mechanism at
the basis of the pathology has been the subject of intense
analysis. The most accredited pathogenetic hypothesis is a
‘‘gain of function’’ of the expanded RNA that is trapped in the
nucleus and misregulates RNA-binding proteins involved in
the splicing process. The finding of a tetranucleotide expansion
in an intron as the cause of DM2 supports the model of a
‘‘toxic’’ effect of the RNA. In fact the same putative nuclear
factor could be sequestered in both DM1 and DM2 and1762 (2006) 329 – 334
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has been demonstrated that CUG- and CCUG-containing
transcripts accumulate in ribonuclear foci both in DM1 and
DM2 cells and alter the regulation and localization of CUG-
binding proteins, including CUG-BP [10] and three different
forms of the RNA-binding protein muscleblind [11,12].
However, the possibility that the pathophysiological differ-
ences between DM1 and DM2 are due, at least in part, also to
the specific genes implicated cannot be ruled out. In fact
DMPK deficient (Dmpk/) mice develop a late-onset,
progressive skeletal myopathy that shares some pathological
features with DM [13]. Other studies demonstrated, in DM1
patients, a reduced DMPK expression from the mutated allele
and a normal expression from the unaffected allele which
results in the down-regulation of the encoded protein especially
marked in the congenital form of the disease [14]. These
findings suggest that, in DM1, pathogenesis may not depend
solely on microsatellite expansion in RNA, but reduced
abundance and/or defective function of the protein may
contribute to the pathological changes of skeletal muscle. A
similar condition may be present in DM2, since the pathogenic
effects of the DM2 mutation take place mainly in skeletal
muscle. It is therefore possible that the protein product of
ZNF9 may play a specific role for the function of skeletal
myofibers. The ZNF9 gene has five exons and encodes for an
highly conserved [15] protein of 19 kDa with seven zinc-finger
domains of the CCHC type. Two main isoforms of ZNF9 have
been found in human cells: ZNF9-alpha and ZNF9-beta [16].
ZNF9-alpha contains an in-frame insert of 21 nucleotides,
which code for an additional seven amino acids between the
first and second zinc finger domains (Fig. 1). Interestingly the
presence of two alternative splicing forms has been found also
in other species such as rat, mouse and Xenopus [17–19]. The
conservation of alternatively spliced forms, suggests specific
roles for them, which however remains unknown. Although
ZNF9 has been proposed to be implicated in several processes
[15,16,20,21], its function is still unclear [17,18]. Among the
proposed functions of ZNF9, a role as a transcriptional
suppressor of human beta-myosin heavy chain (hMHC), which
is constitutively expressed by cardiac and slow skeletal muscle
fibers, is of interest [22]. ZNF9 is also hypothesized to be a
translational repressor of a class of genes called TOP genes,Fig. 1. Schematic representation of the ZNF9 gene and ofwhich encode for ribosomal proteins and other components of
the protein synthesis apparatus [19,23].
To address the function of the ZNF9 protein and, in
particular, the molecular mechanisms by which the (CCTG)n
expansion in its first intron mediates the dominant expression
of the DM2 phenotype, we studied the splicing pattern and the
global level of ZNF9 mRNA and protein in lymphoblastoid
cells from DM2 patients.
2. Materials and methods
2.1. Cell cultures
All patients included in this study have the cardinal clinical features of
DM2, including muscle weakness, electrical myotonia, muscular dystrophy and
cataracts. Molecular characterization at DM2 locus, obtained as described in
Bonifazi et al. [24] , was the following: patient #1 showed a 13.5-kb expansion;
patient #2 has a 10.5-kb expansion, patient #3 and #4 possess 4.5-kb and kb
3.2-kb expansions, respectively. Human Epstein Bar virus (EBV) immortalized
B lymphoblastoid cell lines were established from patients with DM2 and 3
unaffected controls subjects, by using standard technique. All cells were grown
in RPMI-1640 supplemented with 10% fetal calf serum (FCS).
2.2. FISH-RNA
Cultured lymphoblastoid cells were harvested after 48 h from dilution in
fresh medium and washed once in 1 PBS (100 mM Na2HPO4, 20 mM
KH2PO4, 137 mM NaCl, pH 7.4) (Cambrex). Cells were subjected to
centrifugation with Cytospin3 (Shandom) at 400 rpm for 5 min and then fixed
for 10 min at room temperature in 4% formaldehyde (40% liquid stock
purchased from Electron Microscopy Science), 10% acetic acid (Carlo Erba),
1 PBS. After 2 washes in PBS, cells were permeabilized by treatment with
70% ethanol (Carlo Erba) for at least overnight at 4 -C; then they were
rehydrated for 5 min at room temperature, in 2 SSC (300 mM NaCl, 30 mM
sodium citrate, pH 7) (Carlo Erba), 50% formamide, and hybridized overnight
at 37 -C with chemically synthesized (CAGG)10-Cy3 oligonucleotide probe
(SIGMA) in Hybridization Buffer (Vysis). Slides were washed twice for 30 min
in 2 SSC, 50% formamide, at 37 -C and once in 1 PBS and then mounted
with an anti-fade reagent in DAPI (0.1 Ag/ml) (Vector), and observed with an
Olympus fluorescence microscope equipped with a digital camera. Pictures
were elaborated with CytoVysion software (Olympus).
2.3. RNA analysis
For Northern analysis, RNA, prepared by proteinase K method, was
fractionated on formaldehyde-agarose gels and transferred to Gene Screen Plus
membrane (NEN). Northern blots were performed essentially according to thethe alternative splicing generating a and h isoforms.
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prepared by the random primer technique using cDNA fragments isolated from
plasmids.
For Real-Time quantitative PCR (QRT-PCR) cultured lymphoblastoid cells
were separated into nuclear and cytoplasmic fractions using the Nuclei EZ Prep
Isolation kit (SIGMA) following the procedure for suspension cell lines. Total
RNAs from the nuclear pellets and supernatant containing cytoplasmic fraction
were extracted with Rneasy Mini kit (Clontech) and 3 Ag were loaded in a 1.0%
agarose gel. Three Ag of total RNA from nuclear and cytoplasmic cell fractions
were reverse-transcribed to cDNA according to cDNA protocol of High-
Capacity cDNA Archive Kit (Applied Biosystems). Incubation conditions were
the following: 10 min at 25 -C and 2 h at 37 -C. We performed QRT-PCR using
the Taqman system (Applied Biosystem). The expression level of the ZNF9 gene
and of the internal reference (b2-Microglobulin gene) were measured by
multiplex PCR usingAssay-on-demandi gene expression products labeledwith
FAM dye (ZNF9: Hs00231535_m1) or VIC dye (B2M: Acc. #NM_004048),
(Applied Biosystems). The simultaneous measurement of ZNF9-FAM/control
gene-VIC expression permitted normalization of the amount of cDNA added
per sample. We performed each PCR reactions in triplicate using the Taqman
Universal PCR Master Mix and the ABI PRISM 7000 Sequence Detection
System. A comparative threshold cycle (Ct ) was used to determine gene
expression relative to a calibrator (control subjects). Hence, steady-state mRNA
levels were expressed a n-fold difference relative to the calibrator. For each sample,
ZNF9 Ct value was normalized using the formula DCt=CtZNF9CtB2M. To
determine relative expression levels, the following formula was used: DDCt=DCt
sampleDCt calibrator and the value used to plot relative gene expression was
calculated using the expression 2DDCt.
For RT-PCR, 3 Ag of total RNA isolated with RNeasy Mini kit (Clontech)
were reverse-transcribed to cDNA using M-MLV reverse transcriptase
(Invitrogen) according to standard protocol using random hexamers (100 ng/
Al). Amplification of two isoforms was carried out using a-32P-dCTP and
specific primers flanking the exon2–exon3 junction: CNBP14-forward primer
(5V-CTACTGGTGGAGGCCGTGGT-3V) and CNBP15-reverse primer (5V-
AATGACCAG ACTCACCACAGC-3V). These primers generate either a 130-
or a 109-bp fragment corresponding to the a or h ZNF9 isoform, respectively.
Twenty-four cycles of amplification were performed, each consisting of 30 s at
95 -C, 30 s at 64 -C and 60 s at 72 -C, followed by a final 10-min extension at
72 -C. RT-PCR products were separated on a 4% native polyacrylamide gel.
The dried gel was exposed to a phosphoscreen and then analyzed by
PhosphorImager and ImageQuant software (Amersham Biosciences).
2.4. Immunoblotting
Polyclonal antibody against ZNF9 was prepared against a C-terminus
peptide of ZNF9 (conserved among vertebrates). Equal amount of cytoplasmic
extracts from lymphoblastoid cell lines were separated on 12% SDS-
polyacrylamide gel and transferred to Immobilon membrane (Millipore) with
a Hoefer electroblot apparatus. Membranes were incubated with rabbit anti-
ZNF9 or anti-actin antisera (Sigma #A2066) according to manufacturer’s
instructions. Immunoreactive bands were detected by chemiluminescence
(SuperSignal reagent, Pierce) after incubation with peroxidase-conjugated
secondary antibodies (Jackson Immunoresearch). Quantification analyses were
performed by LAS3000 Imaging System (Fuji) and ImageQuant (Amersham
Biosciences) software.Fig. 2. In situ hybridization (RNA FISH) with a (CAGG)10-Cy3 probe on
lymphoblastoid cells nuclei from DM2 patients (A) and normal controls (B).3. Results
3.1. Ribonuclear inclusions in lymphoblastoid cultures from
DM2 patients
Analysis by RNA FISH of primary cells from DM1 and
DM2 patients revealed, in the nucleus, ribonuclear inclusions
containing expanded RNA sequences [5,12,25,26]. The role of
these inclusions in the pathology is not clear. However they are
thought to be associated to the cellular alteration at the basis ofthe clinical phenotype. To verify if expanded ZNF9 transcripts
accumulate as ribonuclear inclusions also in lymphoblastoid
cell lines, we have analyzed, by RNA FISH, different cultures
from DM2 patients. Hybridization with chemically synthesized
(CAGG)10-Cy3 probe, revealed the presence of nuclear spots
(Fig. 2) also visible in DM1 cells and tissues [25,27]. Foci have
not been localized to a particular sub-nuclear structure, their
number resulted extremely variable depending of cell cycle
status and is not correlated with the degree of ZNF9 expansion
in each DM2 patient analyzed. This result indicates that
lymphoblastoid cell lines may represent a useful in vitro
experimental model to study molecular alterations caused by
RNA expansion.
3.2. ZNF9 mRNA expression in DM2 cells
Preliminary QRT-PCR experiments (not shown) on total
RNA from lymphoblastoid cell lines (n =4) from DM2 patients
compared with normal subjects (n=3) indicated that there is
not alteration of ZNF9 mRNA steady state in DM2 cells.
However, in this experiments we could not exclude the
interference of partially processed ZNF9 transcripts. To address
this point, we performed Northern analysis on total RNA and
QRT-PCR experiments on nuclear and cytoplasmic RNA
separately. In Northern experiments we used ribosomal protein
L4 mRNA as a control, whereas QRT-PCR experiments have
been performed in using the h2-Microglobulin housekeeping
gene as internal control. Northern analysis (Fig. 3A) confirms
that there is not evident alteration in the amount or size of
ZNF9 mRNA in DM2 cells. Similarly QRT-PCR shows (Fig.
3B, D) that both nuclear and cytoplasmic ZNF9 mRNA levels
are not affected at detectable level in cells from DM2 patients.
As the relative amount of a and h splicing variants in ZNF9
mRNA cannot be investigated by the QRT-PCR technique, we
performed labeled RT-PCR experiments using primers flanking
the exon2–exon3 junction of the transcript. Amplification
products include both isoforms as schematized in Fig. 4.
Amplified DNA fragments from DM2 cell lines (n=4) and
controls (n=3) were separated by electrophoresis on a 4%
native polyacrylamide gel and visualized by autoradiography.
Quantification of the amplified bands by PhosphorImager
analysis indicates that the ratio of ZNF9 splicing isoforms in
DM2 cells is comparable to control. Therefore, ZNF9 splicing
pattern does not appear to be altered in lymphoblastoid cell
lines from DM2 patients.
Fig. 4. Equivalent amounts of total RNA isolated from 3 control (C1–C3) and
4 DM2 lymphoblastoid cell lines (P1–P4) were subjected to RT-PCR analysis
using primers flanking the alternatively spliced region and separated on a 4%
native polyacrylamide gel. (A) Example of gel with plasmid templates as
positive controls (a and h). (B) The relative amount of the a- and h-ZNF9
isoforms (130- and 109-bp fragments, respectively) was quantified by
PhosphorImager. The results of at least three experiments are reported (with
S.E. bars) as a bar graph. (C) Schema of the amplification of the two isoforms
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A polyclonal antiserum against a ZNF9 carboxy-terminus
peptide was originally tested on Xenopus extracts [28]. We first
validated the antiserum on human recombinant ZNF9 and
human lymphoblastoid cell extracts (Fig. 5A). The antiserum
was then used in Western blot analysis of lymphoblastoid cell
lines from DM2 patients (n =3 or 4) and controls (n =3). For
the normalization of the signals we used antisera against actin.
The results are reported in Fig. 5B as a bar graph of the average
of multiple experiments with S.E. The experiments were
performed at least three times (samples with the error bar) or
twice (samples without error bar). Examples of the Western
analysis with the different antisera are showed in Fig. 5C. The
analysis of the data shows that ZNF9 protein level does not
appear to be consistently altered in DM2 cells.
4. Discussion
DM is another example of a human disorder caused by
expansion of simple DNA repeats. The repeat expansion may
occur within the coding regions of disease-causing genes or, as
in the case of both DM1 and DM2, in the untranslated regions or
intervening sequences where they may cause transcriptional or
post-transcriptional alteration of gene expression. In DM1 the
unstable CTG repeat is localized in the 3VUTR of the DMPK
gene while in DM2 the expansion lies in the first intron of the
ZNF9 gene. The two forms of DM exhibit overlapping clinical
phenotype that affects, besides muscle, also eye, heart, and
endocrine system. Other features of the disease, as congenital
form or the severe central nervous system involvement appear
DM1-specific. Direct effect of the expansion on DMPK level
was the first obvious suggestion for DM1 cause [2–4]. DMPK
is a serine/threonine kinase that can undergo autophosphoryla-Fig. 3. (A) Five Ag of total RNA from control cell lines (C1–C3) and DM2 cell
lines (P1–P3) was separated of formaldehyde/agarose gel and transferred on
membrane. Hybridization was carried out with the indicated probes. (B)
Nuclear or cytoplasmic RNA from DM2 lymphoblastoid cells lines (n =4) and
normal controls (n =3) was analyzed by Quantitative Real Time PCR with a
ZNF9 specific probe and h2M housekeeping gene as internal control. Results
of three independent experiments (with S.E. bars) normalized with h2M
mRNA level are reported. C corresponds to the media of data from 3 normal
controls and has been set as 1.
Fig. 5. Western blot analysis of ZNF9. (A) 100 ng of recombinant GST-ZNF9
and 20 Ag of cytoplasmic extract from lymphoblastoid cultured cells were
subjected to Western blotting using anti-ZNF9 antiserum. (B) Equal amounts o
cell extracts (30 Ag of proteins) from control cell lines (C1–C3) and DM2 cel
lines (P1–P4) were subjected to Western blotting using anti-ZNF9 and anti
actin antisera. Chemiluminescence analyses were performed by LAS3000
Imaging System (Fuji) and ImageQuant (Amersham Biosciences) software. The
results are reported in the bar graph as ratio ZNF9/actin with the control C1 se
to 1.0. The results represent the mean of at least three (samples with S.E. bars
except P4 which is a single experiment. (C) Examples of Western analysis with
the indicated antisera..tion [29] and can phosphorylate myosin phosphatase (MYPT1)
inhibiting its activity [30]. An important consequence of this
inhibition is an increase in the levels of phosphorylated myosin
which in turn results in calcium sensitization of smooth muscle
and cytoskeletal changes in non-muscle cells [31]. However, the
role of DMPK haploinsufficiency in DM1 pathology is still
controversial. In fact DMPK knock out mice do not show the
myotonia or cataracts characteristic of DM1, although they
developed late-onset skeletal myopathy and a condition similar
to the DM1 cardiac phenotype [13]. Therefore, these results
suggest that DMPK haploinsufficiency alone cannot be
responsible for the development of DM1 but it can play a
contributory role. Moreover, other experimental studies dem-f
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mutated allele expression, and this is particular marked in
muscle from patients affected by the congenital form of the
disorder [14,32,33]. On the basis of these reports, our study
addresses the impact of the (CCTG)n expansion, which can
reach the 11.000 repeats, on the ZNF9 mRNA and protein levels
in cells from DM2 patients. Although several roles have been
proposed for ZNF9 [15,16,20,21], a solid evidence for any of
them is still lacking. Therefore, at this stage, it is impracticable
to speculate on the possible contributory role of ZNF9 in DM2.
However we think it is important anyway to establish if, as a
consequence of the repeat expansion, the expression of the
ZNF9 gene is altered at any the level (transcriptional, post-
transcriptional, translational, post-translational) in cells of DM2
patients. For this purpose we have collected immortalized
lymphoblastoid cultures from DM2 patients and from control
donors to be used as experimental system. This cell type is not
suitable to address the main, tissue-specific alterations of DM2.
However the advantage of their indefinite lifespan and the
minimal impact on the donor patients make them attractive for
the study of basic functions. Initially, we have verified the
presence in this cell type of the ribonuclear inclusions that have
been described both in DM1 and DM2 cells [26]. The variable
number of RNA foci observed in cells from patients, but not in
the controls, indicates that lymphoblastoid cells can be used to
address the effect of the RNA expansion on general cellular
functions. Therefore we carried out an analysis of ZNF9
expression both at RNA and protein levels in cells from DM2
patients and controls. Analysis of total RNA by Northern blot as
well as of nuclear and cytoplasmic mRNA by QRT-PCR, did
not show significant alterations of ZNF9 transcript level in DM2
cells. This suggests that nuclear foci, detected with a probe
complementary to the expanded RNA, are probably due to the
accumulation of the spliced first intron (or part of it). Similarly
the analysis of the splicing isoforms did not reveal modification
of the ratio between the alpha and beta forms. Finally, Western
analysis showed some variability with the DM2 samples leaving
open the question if a more sensitive technique could detect a
consistently lower amount of ZNF9 in DM2 samples. In any
case at this stage we can conclude that (CCTG)n expansion does
not have an evident direct consequence on transcript and protein
level as well as on the splicing pattern of the ZNF9 gene in the
DM2 lymphoblastoid cells we have analyzed.
These observations are consistent with the recent report of
three DM2 patients in one large consanguineous family from
Afghanistan, with two mutant ZNF9 alleles [34]. Homozygos-
ity for the DM2 expansion does not seem to alter the disease
phenotype as compared with the heterozygous state and this
observation seems to exclude a direct role of the ZNF9 gene on
the disease pathogenesis. Similarly to what already demon-
strated for DM1, the most accredited mechanism leading DM
clinical outcome, remains a dominant toxic effect of the repeat
expansions on muscle tissue. Investigation on the mechanism
of RNA dominance are focusing on the hypothesis of protein
sequestration or alteration by the expanded transcript. Accord-
ing to this model proteins required for processing of nuclear
RNA, such as MBNL and CUGBP, would be removed from theother transcripts inhibiting cellular function and tissue devel-
opment [35]. Both proteins have in fact a role in affecting
alternative splicing through antagonistic effects in which CUG-
BP promotes the inclusion of exons that are normally expressed
during fetal development, whereas MBNL1 favours adult
splicing isoform [36]. Changes in the regulation of these
proteins can cause aberrant splicing of downstream genes
expressed in DM target tissues. Dysregulation of the insulin
receptor (IR), chloride channel (Clcn1), Skeletal Ryanodyne
receptor (RyR1) and Sarcoplasmic reticulum Ca2+-ATPase
(SERCA) mRNAs has been observed in muscle cells from DM
patients [37–41]. A similar disease mechanism is emerging
also in the brain, where MBNL proteins are sequestred by the
DMPK mutant transcript and a particular biochemical profile of
pathological tau proteins is present [42–44]. Alteration in the
IR gene splicing lead to the insulin insensitivity and a
predisposition to diabetes [38], while alteration in the Clcn1,
Ryr1 and SERCA transcripts might contribute to the membrane
hyperexcitability and Ca2+ homeostasis impairment of DM
muscle cells. Our findings that the steady-state levels of ZNF9
mRNA and protein are not significantly altered in cells from
DM2 patients support a pathogenetic model in which the DM1
and DM2 overlapping clinical phenotypes originate from a
common trans-acting mechanism involving the misregulation
of a specific subset of identical genes.
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